Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011.

OBJECTIVES To determine if the disparities in the outcome between white (W) and African American (AA) patients with uterine serous carcinoma (USC) have changed over time. METHODS Women with USC were identified using the SEER database from 1988 to 2011 (N=7667). Years of the study were divided into three periods (1988-1997, 1998-2004 and 2005-2011). Overall (OS) and disease-specific survivals (DSS) was estimated. RESULTS Over the three time periods, African American patients continued to be younger and less likely to have cancer directed surgery and extensive lymphadenectomy when compared to white patients. In multivariable analysis adjusting for age, race, marital status, stage, cancer-directed surgery, extent of lymphadenectomy, adjuvant radiation, and geographic location, AA was significantly associated with worse DSS and OS in the three time periods compared to white race. African American patients were 29% (95% CI 1.03-1.62, p=0.027) in 1988-1997, 40% in 1998-2004 (95% CI 1.21-1.63, p<0.0001) and 34% in 2005-2011 (95% CI 1.13-1.59, p=0.0008) more likely to die from uterine cancer compared to their white counterparts. A slight improvement in the difference in OS over time was noted comparing African American and white patients. African American patients were 46% (95% CI 1.23-1.73, p<0.0001) in 1988-1997, 39% in 1998-2004 (95% CI 1.23-1.56, p<0.0001) and 26% in 2005-2011 (95% CI 1.10-1.45, p<0.0001) more likely to die from any cause compared to their white counterparts. CONCLUSIONS Significant improvement in outcome was noted in both racial groups over time. However, African American patients continued to have worse outcome than white patients over time.

[1]  O. Yap,et al.  Racial and ethnic disparities in cancers of the uterine corpus. , 2006, Journal of the National Medical Association.

[2]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Olson,et al.  The influence of comorbid conditions on racial disparities in endometrial cancer survival. , 2014, American journal of obstetrics and gynecology.

[4]  R. Burger,et al.  Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Waggoner,et al.  Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. , 2015, Gynecologic oncology.

[6]  Deepa Naishadham,et al.  Cancer statistics for African Americans, 2013 , 2013, CA: a cancer journal for clinicians.

[7]  E. Yordan,et al.  Optimal surgical debulking in uterine papillary serous carcinoma affects survival. , 2011, Gynecologic oncology.

[8]  T. Herzog,et al.  Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. , 2003, Gynecologic oncology.

[9]  V. Abeler,et al.  Clear-cell and papillary serous cancer: treatment options. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[10]  R. Kempson,et al.  Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.

[11]  M. Maiman,et al.  Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. , 1997, Gynecologic oncology.

[12]  J. Thigpen,et al.  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Racial Disparities in Treatment of High-Grade Endometrial Cancer in the Medicare Population , 2015, Obstetrics and gynecology.

[14]  L. Havrilesky,et al.  Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma , 2009, Cancer.

[15]  R. Bentley,et al.  Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  K. Armstrong,et al.  Differences in treatment and outcome between African-American and white women with endometrial cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Gruber,et al.  Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. , 2004, American journal of public health.

[18]  F. Montz,et al.  The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. , 2001, Gynecologic oncology.

[19]  Alicia Samuels,et al.  Cancer Statistics for African Americans , 2002, CA: a cancer journal for clinicians.

[20]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[21]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[22]  G. Maxwell,et al.  Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[23]  R. Berkowitz,et al.  Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. , 2014, Gynecologic oncology.

[24]  G. Parham,et al.  The National Cancer Data Base report on endometrial carcinoma in African‐American women , 1998, Cancer.

[25]  G. Fleming,et al.  Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma , 2006, Cancer.

[26]  M. Rotman,et al.  Poor survival of black patients in carcinoma of the endometrium. , 1993, International journal of radiation oncology, biology, physics.

[27]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. McAlpine,et al.  Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. , 2004, Gynecologic oncology.

[29]  J. Nicklin,et al.  Endometrial papillary serous carcinoma: patterns of spread and treatment. , 1996, Clinical obstetrics and gynecology.